An exciting new breast cancer drug, palbociclib (Ibrance), is a step closer to becoming available in Australia. Palbociclib is an effective new first-line treatment for hormone receptor positive, HER2-negative metastatic breast cancer. It is given with a hormone therapy drug – letrozole or anastrozole.
The PALOMA2 clinical trial found that the combination of palbociclib and letrozole extended progression-free survival (the length of time before the cancer spreads) to 20.2 months, compared with 10.2 months for women on the trial who took letrozole only.
The trial also found that palbociclib, which is an oral treatment (tablet), was well tolerated.
Applications are currently before the Australian Therapeutic Goods Administration and the Pharmaceutical Benefits Advisory Committee (PBAC) to have palbociclib registered for sale in Australia and listed on the Pharmaceutical Benefits Scheme (PBS) as a first-line treatment for postmenopausal women with hormone receptor positive, HER2-negative metastatic breast cancer.
BCNA has made a submission to the PBAC in support of listing palbociclib on the PBS. You can read it on the Submissions page of our website, bcna.org.au.
Another trial, PALOMA3, is currently investigating the combination of palbociclib and fulvestrant (Faslodex) as a later line treatment. This combination has been approved in other countries around the world. However, the current PBAC application does not include it.
Add your voice to our palbociclib campaign by visiting our website, bcna.org.au, and following the link to the petition.